SKYSONA

This brand name is authorized in Estonia, France, Lithuania, Poland

Active ingredients

The drug SKYSONA contains one active pharmaceutical ingredient (API):

1 Elivaldogene autotemcel
UNII KUM75TD6SG - ELIVALDOGENE AUTOTEMCEL

Elivaldogene autotemcel is indicated for the treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an ABCD1 genetic mutation. Elivaldogene autotemcel adds functional copies of the ABCD1 cDNA into patients' HSCs through transduction of autologous CD34+ cells with Lenti-D LVV. Following successful engraftment with genetically modified cells, the expression of ALDP is expected to be life-long.

Read about Elivaldogene autotemcel

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
SKYSONA Dispersion for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N07 Other nervous system drugs N Nervous system
Discover more medicines within N07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1858596
Country: FR Base de données publique des médicaments Identifier(s): 65249832
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1093082
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100456917

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.